title: Effect of peanut oil and randomized peanut oil on cholesterol and oleic acid absorption, transport, and distribution in the lymph of the rat.
abstract: Peanut oil was shown to be atherogenic in cholesterol-fed rats, rabbits, and monkeys. However, after randomization, a process in which the fatty acids in peanut oil are randomly rearranged, its atherogenicity was significantly reduced in cholesterol-fed rabbits and monkeys. The mechanism for this effect remains unknown. This study was designed to investigate whether the absorption, transport and distribution of dietary cholesterol and oleic acid in the lymph were altered in the presence of peanut oil or randomized peanut oil. Previous investigators collected lymph through the mesenteric duct for 6 h and analyzed lymph for cholesterol. In the present study, lymph fluids were collected at timed intervals for up to 8 h and then at 24 h via the thoracic duct. Cholesterol and oleic acid (fatty acid) were estimated not only in the whole lymph but also in lymph lipoprotein fractions and in major lipid fractions. A 24-h lymph collection will enhance accuracy as short-term fluctuations in lipid absorption will not affect the results. Thoracic duct lymph collection is quantitative compared to mesenteric duct lymph collection, which provides only a fraction of the total lymph. Rats were given a lipid emulsion containing either peanut oil or randomized peanut oil. The emulsion also contained cholesterol, oleic acid, and sodium taurocholate in saline and was given through a duodenal catheter. Results show that absorption, transport, and distribution of cholesterol and oleic acid in the lymph fluids were similar in both dietary groups. These results suggest that the atherogenicity of peanut oil may be due to other events taking place subsequent to the release of cholesterol-containing chylomicrons and very low density lipoprotein by the small intestinal epithelial cells into the blood or may be due to the triglyceride structure itself.
authors.affiliation: Division of Science and Applied Technology, US Food and Drug Administration, Laurel, Maryland 20708, USA. sxs@cssan.fda.gov
authors.forename: S
authors.initials: S
authors.lastname: Satchithanandam
authors.forename: T J
authors.initials: TJ
authors.lastname: Flynn
authors.forename: R J
authors.initials: RJ
authors.lastname: Calvert
authors.forename: D
authors.initials: D
authors.lastname: Kritchevsky
mesh_terms: D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D002784:Cholesterol / Q000378:metabolism*; D002788:Cholesterol Esters / Q000378:metabolism; D002914:Chylomicrons / Q000378:metabolism; D005227:Fatty Acids / Q000737:chemistry; D005989:Glycerides / Q000378:metabolism; D008074:Lipoproteins / Q000378:metabolism; D008196:Lymph / Q000378:metabolism*; D008297:Male; D019301:Oleic Acid / Q000378:metabolism*; D000074241:Peanut Oil; D010938:Plant Oils / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D002788:Cholesterol Esters; D002914:Chylomicrons; D005227:Fatty Acids; D005989:Glycerides; D008074:Lipoproteins; D000074241:Peanut Oil; D010938:Plant Oils; D019301:Oleic Acid; D002784:Cholesterol